Rapid adaptation of SARS-CoV-2 in BALB/c mice: Novel mouse model for vaccine efficacy

Hongjing Gu,Qi Chen,Guan Yang,Lei He,Hang Fan,Yong-Qiang Deng,Yanxiao Wang,Yue Teng,Zhongpeng Zhao,Yujun Cui,Yuchang Li,Xiao-Feng Li,Jiangfan Li,Nana Zhang,Xiaolan Yang,Shaolong Chen,Guangyu Zhao,Xiliang Wang,Deyan Luo,Hui Wang,Xiao Yang,Yan Li,Gencheng Han,Yuxian He,Xiaojun Zhou,Shusheng Geng,Xiaoli Sheng,Shibo Jiang,Shihui Sun,Cheng-Feng Qin,Yusen Zhou
DOI: https://doi.org/10.1101/2020.05.02.073411
2020-01-01
bioRxiv
Abstract:Coronavirus disease 2019 (COVID-19) threatens global public health and economy. In order to develop safe and effective vaccines, suitable animal models must be established. Here we report the rapid adaption of SARS-CoV-2 in BALB/c mice, based on which a convenient, economical and effective animal model was developed. Specifically, we found that mouse-adapted SARS-CoV-2 at passage 6 (MACSp6) efficiently infected both aged and young wild-type BALB/c mice, resulting in moderate pneumonia as well as inflammatory responses. The elevated infectivity of MACSp6 in mice could be attributed to the substitution of a key residue (N501Y) in the receptorbinding domain (RBD). Using this novel animal model, we further evaluated the in vivo protective efficacy of an RBD-based SARS-CoV-2 subunit vaccine, which elicited highly potent neutralizing antibodies and conferred full protection against SARS-CoV-2 MACSp6 challenge. This novel mouse model is convenient and effective in evaluating the in vivo protective efficacy of SARS-CoV-2 vaccine. Summary This study describes a unique mouse model for SARS-CoV-2 infection and confirms protective efficacy of a SARS-CoV-2 RBD subunit vaccine. ### Competing Interest Statement The authors have declared no competing interest.
What problem does this paper attempt to address?